Myeloid Cells: Functional Heterogeneity with Therapeutic Promise (K8)
February 23-26, 2026
| Keystone Resort, Keystone, CO, United States
Charlotte L. Scott, Shalin H. Naik and Thomas Fabre
Scholarship Deadline: Oct. 30, 2025 | Abstract Deadline: Feb. 4, 2026 | Early Registration Deadline: Dec. 31, 2025
Monday, February 23, 2026
| 4:00–8:00 PM |
Registration |
|
| 6:00–8:00 PM |
Welcome Mixer |
|
Tuesday, February 24, 2026
| 8:00–9:00 AM |
Welcome and Keynote Address |
|
| |
Shannon J Turley, Genentech, Inc.
Manipulating Stromal-Myeloid Cell Crosstalk for Therapeutic Purposes |
|
| 9:00–11:15 AM |
Myeloid Cell Development, Recruitment and Fate |
|
| |
Shalin H. Naik, Walter & Eliza Hall Institute
Barcoding Human and Mouse Haematopoiesis |
|
| |
Elizabeth Wayne, University of Washington
Engineering Monocyte Cell Fate in Disease |
|
| |
Heping Xu, Westlake University
Airway Neutrophil Recruitment by Alarmin-Loaded Extracellular Lipid Droplets |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:30–9:50 AM |
Coffee Break |
|
| 11:15–1:00 PM |
Poster Setup |
|
| 11:15–2:30 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
|
| 2:30–4:30 PM |
Symposia Spotlight 1: Late-breaking research presentations selected from abstract submissions |
|
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–7:00 PM |
Myeloid Cells in Tumors |
|
| |
Ariel Munitz, Tel Aviv University
Eosinophils in the Tumor Microenvironment |
|
| |
Stefani Spranger, Massachusetts Institute of Technology
The Role of Dendritic Cells in Shaping Anti-Tumor Immunity |
|
| |
Jennifer Guerriero, Brigham and Women's Hospital
Myeloid Cells as Immunotherapy for Breast Cancer |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
Wednesday, February 25, 2026
| 8:00–11:00 AM |
Myeloid Cell Functions in Disease Contexts |
|
| |
Charlotte L. Scott, University of Ghent & VIB
Role of Lipid-Associated Macrophages in Tissue Injury |
|
| |
Lai Guan Ng, Shanghai Immune Therapy Institute
Harnessing Neutrophil Heterogeneity for Biomarker Development and Targeted Treatment |
|
| |
Hawa Racine Thiam, Stanford University
Engineering NETosis in Disease |
|
| |
Florent Ginhoux, Gustave Roussy
DC Heterogeneity in Disease |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:00–9:20 AM |
Coffee Break |
|
| 11:00–1:00 PM |
Poster Setup |
|
| 11:00–5:00 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
|
| 1:45–2:45 PM |
Career Roundtable (Joint) |
|
| 3:00–4:30 PM |
Panel Discussion: Making Sense of the Mess: How to Bring Together the Different Subsets Identified using scRNA-Seq in Different Studies |
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–7:00 PM |
Functional Heterogeneity of Myeloid Cells Across Tissues |
|
| |
Kurt Zimmerman, University of Oklahoma Health Sciences Center
Functional Heterogeneity of Kidney Macrophages |
|
| |
Isabelle C Arnold, University of Zurich
Eosinophils in the Gastrointestinal Tract |
|
| |
David Sancho, Centro Nacional de Investigaciones Cardiovasculares, CNIC
Metabolic Control of Myeloid Cell Function |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
Thursday, February 26, 2026
| 8:00–11:00 AM |
Myeloid Cells in Infection |
|
| |
Calum C. Bain, University of Edinburgh
Role of Macrophages in Pulmonary Infections |
|
| |
Lidia Bosurgi, University Medical Center Hamburg-Eppendorf
Harnessing Macrophage Efferocytosis to Promote Tissue Repair and Remodeling |
|
| |
Bryan D. Bryson, Massachusetts Institute of Technology
Reprogramming Myeloid Cells to Improve Bacterial control |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:00–9:20 AM |
Coffee Break |
|
| 11:00–2:30 PM |
On Own for Lunch |
|
| 2:30–4:30 PM |
Symposia Spotlight 2: Going from scRNA-seq to Meaningful Biology |
|
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–7:00 PM |
Targeting Myeloid Cells in Disease |
|
| |
Thomas Fabre, Pfizer
Utilizing Macrophages to Treat Fibrosis |
|
| |
Filipe Pereira, Lund University and Asgard Therapeutics
Conversion of Cancer Cells into Dendritic Cells to Reinstate Cancer Immunity |
|
| |
Adam Freund, Arda Therapeutics
Evaluating the Consequences of Antibody-Drug Conjugate-Mediated Depletion of Myeloid Cells in Liver Fibrosis |
|
| |
Kristen Radford, University of Queensland
Human DCs in Cancer Models |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–7:15 PM |
Meeting Wrap-Up: Outcomes and Future Directions |
|
| 7:15–8:15 PM |
Social Hour with Dinner |
|
| 8:00–11:00 PM |
Entertainment |
|
Friday, February 27, 2026
